Dye Sensitizers for Photodynamic Therapy.
Dye Sensitizers for Photodynamic Therapy.
复制标题
DOI：
10.3390/ma6030817
复制
发表时间：
2013-03-06
期刊：
影响因子：
--
通讯作者：
Freeman HS
中科院分区：
文献类型：
--
作者：
Ormond AB;Freeman HS
Photofrin®在20世纪90年代首次被批准作为敏化剂用于通过光动力疗法（PDT）治疗癌症。从那时起，已经开发了各种各样的染料敏化剂，并且一些已经被批准用于皮肤和器官癌症以及皮肤疾病如寻常痤疮的PDT治疗。类卟啉衍生物和前体在产生必需的单线态氧方面是最成功的，Photofrin®仍然是最有效的敏化剂（量子产率= 0.89），并且具有广泛的食品和药物管理局（FDA）批准用于治疗多种癌症类型。已获得美国FDA和其他国家监管机构批准的其他类卟啉化合物包括苯并卟啉衍生物单酸环A（BPD-MA）、间-四（羟基苯基）二氢卟酚（m-THPC）、N-乙酰基二氢卟酚e6（NPe 6）和内源性原卟啉IX（PpIX）的前体：1，5-氨基乙酰丙酸（ALA）、氨基乙酰丙酸甲酯（MAL）、六氨基乙酰丙酸（HAL）。虽然没有非卟啉敏化剂已被批准用于PDT应用，但少量蒽醌、吩噻嗪、咕吨、花青和姜黄素类敏化剂正在考虑中，并且一些正在临床试验中进行评估。本综述重点关注PDT的性质、已批准用于PDT的染料增敏剂以及已进入或完成临床试验作为PDT增敏剂的化合物。
Photofrin® was first approved in the 1990s as a sensitizer for use in treating cancer via photodynamic therapy (PDT). Since then a wide variety of dye sensitizers have been developed and a few have been approved for PDT treatment of skin and organ cancers and skin diseases such as acne vulgaris. Porphyrinoid derivatives and precursors have been the most successful in producing requisite singlet oxygen, with Photofrin® still remaining the most efficient sensitizer (quantum yield = 0.89) and having broad food and drug administration (FDA) approval for treatment of multiple cancer types. Other porphyrinoid compounds that have received approval from US FDA and regulatory authorities in other countries include benzoporphyrin derivative monoacid ring A (BPD-MA), meta-tetra(hydroxyphenyl)chlorin (m-THPC), N-aspartyl chlorin e6 (NPe6), and precursors to endogenous protoporphyrin IX (PpIX): 1,5-aminolevulinic acid (ALA), methyl aminolevulinate (MAL), hexaminolevulinate (HAL). Although no non-porphyrin sensitizer has been approved for PDT applications, a small number of anthraquinone, phenothiazine, xanthene, cyanine, and curcuminoid sensitizers are under consideration and some are being evaluated in clinical trials. This review focuses on the nature of PDT, dye sensitizers that have been approved for use in PDT, and compounds that have entered or completed clinical trials as PDT sensitizers.
登录
查看更多内容
影响因子：
3.1
作者：
Brun, PH;DeGroot, JL;Pottier, RH
通讯作者：
Pottier, RH
影响因子：
3.1
作者：
Hatz, Sonja;Lambert, John D. C.;Ogilby, Peter R.
通讯作者：
Ogilby, Peter R.
影响因子：
6.6
作者：
Chevalier, Simone;Anidjar, Maurice;Elhilali, Mostafa
通讯作者：
Elhilali, Mostafa
影响因子：
--
作者：
Araujo, Natalia Costa;Fontana, Carla Raquel;Bagnato, Vanderlei Salvador
通讯作者：
Bagnato, Vanderlei Salvador
影响因子：
11.2
作者：
Furre, IE;Shahzidi, S;Peng, Q
通讯作者：
Peng, Q